Gene
UGT1A1
UGT1A1 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (1), Actionable biomarkers (5), Trial mentions (470), and 6 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
1 more section with rows · 3 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention UGT1A1. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start and 3 with no date at all.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 20 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 35 of 8,738 | 0.40% | not measured | |
| 2025 | 46 of 8,875 | 0.52% | not measured | |
| 2024 | 59 of 8,597 | 0.69% | not measured | |
| 2023 | 33 of 8,275 | 0.40% | 27 of 11,460 | 0.24% |
| 2022 | 23 of 8,285 | 0.28% | 20 of 13,598 | 0.15% |
| 2021 | 43 of 8,692 | 0.49% | 38 of 15,045 | 0.25% |
| 2020 | 29 of 7,640 | 0.38% | 24 of 14,459 | 0.17% |
| 2019 | 26 of 7,300 | 0.36% | 25 of 12,159 | 0.21% |
| 2018 | 16 of 6,927 | 0.23% | 26 of 11,854 | 0.22% |
| 2017 | 24 of 6,558 | 0.37% | 20 of 11,595 | 0.17% |
Showing 10 of 37 years.
Assay-provider ledger (1)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| Pasteur-Cerba | Diagnostic provider | Clinical validation | 1 | March 01, 2011 |
Actionable biomarkers (5)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| UGT1A1 biallelic inactivation | Irinotecan | reduced sensitivity | No disease recorded | Cancer Genome Interpreter |
| UGT1A1 (G71R,P229Q) | NILOTINIB | other | No disease recorded | Cancer Genome Interpreter |
| UGT1A1 biallelic inactivation | NILOTINIB | other | No disease recorded | Cancer Genome Interpreter |
| UGT1A1 (G71R,P229Q) | Irinotecan | reduced sensitivity | No disease recorded | Cancer Genome Interpreter |
| UGT1A1 biallelic inactivation | PAZOPANIB | other | No disease recorded | Cancer Genome Interpreter |
Trial mentions (470)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT05450822 | Trial biospecimen (AACT) |
| NCT06509906 | Trial eligibility (AACT) |
| NCT03837977 | Trial eligibility (AACT) |
| NCT03824899 | Trial eligibility (AACT) |
| NCT06719310 | Trial eligibility (AACT) |
Showing 5 of 470 trial mentions.
Target-disease associations (210)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| 3-carboxy-4-methyl-5-pentyl-2-furanpropionate (3-CMPFP) measurement | measurement | GWAS credible sets |
| 8-methoxykynurenate measurement | measurement | GWAS credible sets |
| Abnormality of skin pigmentation | phenotype | GWAS credible sets |
| Abnormality of the liver | phenotype | GWAS credible sets |
| Barrett's esophagus | gastrointestinal disease | Expression Atlas |
Showing 5 of 210 associations.
Vendor sourcing (1,504)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| 3billion, Inc. (South Korea) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | Functional studies provide strong evidence of the variant having a damaging effect on the gene or gene product (PMID:7852413, PS3_S). In silico tool predicti... | View ClinVar record SCV002058605.1 |
| 4SC (Germany) | Trial sponsor | Named in trial exclusion criteriaTrial eligibility criteria | Phase I: * Patients who have received previous treatment with an HDAC inhibitor * Anticipation of need for a major surgical procedure or radiation therapy (... | View trial NCT01277406 |
| 4SC (Germany) | Trial sponsor | Mentioned in trial textTrial free-text mention | UGT1A1 | View trial NCT01277406 |
| ADIR, a Servier Group company | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * Male or female aged ≥ 18 years; * Patients with cytologically confirmed and documented de novo, secondary or therapy-related AML, excluding acute promye... | View trial NCT02979366 |
| ADIR, a Servier Group company | Trial collaborator | Mentioned in trial textTrial free-text mention | UGT1A1 | View trial NCT02979366 |
Showing 5 of 1,504 sourcing records.
Trial-cited literature (360)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| A phase I study of liposomal Irinotecan (ONIVYDE®) in combination with TAS-102 (LONSURF®) in refractory solid tumors. | Investigational new drugs | 2025 | 3 |
| PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancreatic cancer. | Investigational new drugs | 2025 | 3 |
| Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial. | Cancer communications (London, England) | 2025 | 2 |
| JNJ-10450232 (NTM-006), A novel non-opioid with structural similarities to acetaminophen, produces relatively long-lasting analgesia after a single dose in patients undergoing 3rd molar extraction. | Regulatory toxicology and pharmacology : RTP | 2025 | 2 |
| Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer-study protocol of the OPTIMA study. | BMC cancer | 2025 | 1 |
Showing 5 of 360 papers.
Protein variant mentions (41)
Shown in this order: alphabetical by variant.
| Variant | Distinct papers | Year range | Sample papers |
|---|---|---|---|
| p.A46V | 1 | 2015 | PMID 25741868 |
| p.D256N | 1 | 2011 | PMID 21287160 |
| p.D359N | 1 | 2015 | PMID 25741868 |
| p.E92G | 1 | 2014 | PMID 25151562 |
| p.E92Q | 1 | 2014 | PMID 24672249 |
Showing 5 of 41 variants.
Literature-extracted relations (144)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Irinotecan | Chemical | associate |
Efficacy and safety of regorafenib plus FOLFIRI with <i>UGT1A1</i> genotyping-guided irinotecan dose escalation against metastatic colorectal cancer: a multicenter, phase II, open-label, two-arm randomized controlled tria. | 2025 |
| "Capecitabine" | Chemical | associate |
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial. | 2025 |
| Irinotecan | Chemical | associate |
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial. | 2025 |
| Irinotecan | Chemical | associate |
Evaluation of potential biomarkers during irinotecan-based systemic treatment for colorectal cancer-study protocol of the OPTIMA study. | 2025 |
| Epoprostenol | Chemical | associate |
Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. | 2025 |
Showing 5 of 144 relation assertions.
Organizations publishing (388)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Government of the United States of America | Government | 14 | 2012 to 2021 |
| University of Cape Town | Academic | 12 | 2018 to 2023 |
| Mayo Clinic | Hospital | 10 | 2011 to 2023 |
| National Cancer Center Hospital East | Hospital | 10 | 2015 to 2025 |
| University of Pennsylvania | Academic | 10 | 2017 to 2023 |
Showing 5 of 388 organizations.
Where UGT1A1 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- disorder of visual system
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- infectious disease
- integumentary system disease
- measurement
- nervous system disease
- nutritional or metabolic disease
- phenotype
- pregnancy or perinatal disease
- reproductive system or breast disease
177 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, and human sample screening reference.